Alzheimer’s Med Continues to Deliver Benefit at 3 Years
Data from the TRAILBLAZER-ALZ 2 long-term extension (LTE) study demonstrated that donanemab (Kisunla, Eli Lilly and Company) continues…
ADHD Meds Offer Benefits Far Beyond Core Symptom Relief
Attention-deficit/hyperactivity disorder (ADHD) medications appeared to reduce the risk of suicide, drug misuse, transport incidents, and criminal activity,…